Correction: STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
Executive Summary
In the previous version of this article it was not stated that the full data set of Vertex's 194 patient clinical study had been reported. This was incorrect as the full data set was released by the company and discussed in a conference call on April 18. That press release included a table showing changes relative to placebo, for the secondary endpoint of FEV1 showing that only the top two doses were significantly different from placebo and the highest doses had a lower efficacy than the second highest doses.